Table of Contents Author Guidelines Submit a Manuscript
Journal of Obesity
Volume 2010, Article ID 359527, 5 pages
http://dx.doi.org/10.1155/2010/359527
Research Article

Effect of VPAC1 Blockade on Adipose Tissue Formation and Composition in Mouse Models of Nutritionally Induced Obesity

Center for Molecular and Vascular Biology, KU Leuven, Campus Gasthuisberg, O & N 1, Herestraat 49, P.O. Box 911, B-3000 Leuven, Belgium

Received 14 December 2009; Accepted 18 May 2010

Academic Editor: Renato Pasquali

Copyright © 2010 H. Roger Lijnen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. L. Crandall, G. J. Hausman, and J. G. Kral, “A review of the microcirculation of adipose tissue: anatomic, metabolic, and angiogenic perspectives,” Microcirculation, vol. 4, no. 2, pp. 211–232, 1997. View at Google Scholar · View at Scopus
  2. M. Nakata, D. Kohno, N. Shintani et al., “PACAP deficient mice display reduced carbohydrate intake and PACAP activates NPY-containing neurons in the rat hypothalamic arcuate nucleus,” Neuroscience Letters, vol. 370, no. 2-3, pp. 252–256, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Tomimoto, T. Ojika, N. Shintani et al., “Markedly reduced white adipose tissue and increased insulin sensitivity in adcyap1-deficient mice,” Journal of Pharmacological Sciences, vol. 107, no. 1, pp. 41–48, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. B. A. Adams, S. L. Gray, E. R. Isaac, A. C. Bianco, A. J. Vidal-Puig, and N. M. Sherwood, “Feeding and metabolism in mice lacking pituitary adenylate cyclase-activating polypeptide,” Endocrinology, vol. 149, no. 4, pp. 1571–1580, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. M. S. Winzell and B. Ahrén, “Role of VIP and PACAP in islet function,” Peptides, vol. 28, no. 9, pp. 1805–1813, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. J. P. Segal, N. R. Stallings, C. E. Lee et al., “Use of laser-capture microdissection for the identification of marker genes for the ventromedial hypothalamic nucleus,” Journal of Neuroscience, vol. 25, no. 16, pp. 4181–4188, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. J. E. Morley, M. Horowitz, P. M. K. Morley, and J. F. Flood, “Pituitary adenylate cyclase activating polypeptide (PACAP) reduces food intake in mice,” Peptides, vol. 13, no. 6, pp. 1133–1135, 1992. View at Publisher · View at Google Scholar · View at Scopus
  8. J. C. Reubi, “In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues: clinical implications,” Annals of the New York Academy of Sciences, vol. 921, pp. 1–25, 2000. View at Google Scholar · View at Scopus
  9. R. J. Yu, L. Zhang, T. H. Yi et al., “In vivo anti-obesity effect of the agonist for receptor VPAC1,” Acta Physiologica Sinica, vol. 60, pp. 751–758, 2008. View at Google Scholar
  10. L. Åkesson, B. Ahrén, G. Edgren, and E. Degerman, “VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes,” Endocrinology, vol. 146, no. 2, pp. 744–750, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Freson, H. Hashimoto, C. Thys et al., “The pituitary adenylate cyclase-activating polypeptide is a physiological inhibitor of platelet activation,” Journal of Clinical Investigation, vol. 113, no. 6, pp. 905–912, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Freson, K. Peeters, R. De Vos et al., “PACAP and its receptor VPAC1 regulate megakaryocyte maturation: therapeutic implications,” Blood, vol. 111, no. 4, pp. 1885–1893, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. H. R. Lijnen, E. Maquoi, D. Demeulemeester, B. Van Hoef, and D. Collen, “Modulation of fibrinolytic and gelatinolytic activity during adipose tissue development in a mouse model of nutritionally induced obesity,” Thrombosis and Haemostasis, vol. 88, no. 2, pp. 345–353, 2002. View at Google Scholar · View at Scopus
  14. A. R. Giles, “Guidelines for the use of animals in biomedical research,” Thrombosis and Haemostasis, vol. 58, no. 4, pp. 1078–1084, 1987. View at Google Scholar · View at Scopus
  15. G. Voros, E. Maquoi, D. Demeulemeester, N. Clerx, D. Collen, and H. R. Lijnen, “Modulation of angiogenesis during adipose tissue development in murine models of obesity,” Endocrinology, vol. 146, no. 10, pp. 4545–4554, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Wei and S. Mojsov, “Tissue specific expression of different human receptor types for pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide: implications for their role in human physiology,” Journal of Neuroendocrinology, vol. 8, no. 11, pp. 811–817, 1996. View at Publisher · View at Google Scholar · View at Scopus
  17. M. S. Winzell and B. Ahrén, “G-protein-coupled receptors and islet function-implications for treatment of type 2 diabetes,” Pharmacology and Therapeutics, vol. 116, no. 3, pp. 437–448, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. J. C. Reubi, “In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues: clinical implications,” Annals of the New York Academy of Sciences, vol. 921, pp. 1–25, 2000. View at Google Scholar · View at Scopus
  19. S. M. Knudsen, J. W. Tams, and J. Fahrenkrug, “Role of second extracellular loop in the function of human vasoactive intestinal polypeptide/pituitary adenylate cyclase activating polypeptide receptor 1 (hVPAC1R),” Journal of Molecular Neuroscience, vol. 14, no. 3, pp. 137–146, 2000. View at Google Scholar · View at Scopus
  20. J. N. Fain, A. K. Madan, M. L. Hiler, P. Cheema, and S. W. Bahouth, “Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans,” Endocrinology, vol. 145, no. 5, pp. 2273–2282, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. B. D. Green, N. Irwin, R. S. Cassidy, V. A. Gault, and P. R. Flatt, “Long-term administration of PACAP receptor antagonist, PACAP[6–27], impairs glucose tolerance and insulin sensitivity in obese diabetic ob/ob mice,” Peptides, vol. 27, no. 9, pp. 2343–2349, 2006. View at Publisher · View at Google Scholar · View at Scopus